Leaner Kabi Drives Higher Savings Goal For Fresenius, China ‘Soft’ In 2024
German Firm Commits To 2024 Biosimilars EBITDA Goal In Busy Q4 Call
Fresenius Kabi insists there is a “business plan behind everything” as it divulged a higher cost savings goal for the end of next year, following a fruitful 2023. But queries over margins led the company to stress that it was combatting a variety of uncertainties, especially in China and for its burgeoning biosimilars unit.
